Nemolizumab Update: Galderma’s IL-31 Blocker Receives Filing Acceptances for PN and AD in Four More Countries
Galderma’s nemolizumab has received filing acceptances for prurigo nodularis (PN) and atopic dermatitis (AD) in Australia, Singapore, Switzerland, and the United Kingdom. These countries or regulatory authorities are members of the Access Consortium. An approval decision is expected from the consortium next year. Nemolizumab inhibits interleukin (IL)-31 signaling to provide relief from itch. These acceptances […]